Skip to main content

Table 1 Classification of Participants demographic and clinical diagnosis based on age group

From: Immunohistochemical expression of PAX-8 in Sudanese patients diagnosed with malignant female reproductive tract tumors

 

Age group no. (%)

Total no. 60

P value

40—49 years

50—59 years

60—69 years

70—79 years

Residence of patient

 Central Sudan

2 (10.5)

12 (63.2)

4 (21.1)

1 (5.3)

19 (31.7)

0.550

 East Sudan

1 (16.7)

5 (83.3)

0 (0.0)

0 (0.0)

6 (10.0)

 West Sudan

6 (22.2)

10 (37.0)

9 (33.3)

2 (7.4)

27 (45.0)

 North Sudan

2 (25.0)

3 (37.5)

3 (37.5)

0 (0.0)

8 (13.3)

Site of cancer

 Cervix

10 (19.6)

25 (49.0)

13 (25.5)

3 (5.9)

51 (85.0)

0.885

 Endometrium

1 (20.0)

3 (60.0)

1 (20.0)

0 (0.0)

5 (8.3)

 Ovary

0 (0.0)

2 (40.0)

2 (40.0)

0 (0.0)

4 (6.7)

Cancer histological type

 SCC

9 (20.0)

22 (48.9)

13 (28.9)

1 (2.2)

45 (75.0)

0.330

 Adenocarcinoma

2 (13.0)

8 (53.3)

3 (20.0)

2 (13.3)

15 (25.0)

FIGO staging

 Stage 1

0 (0.0)

2 (66.7)

1 (33.3)

0 (0.0)

3 (5.0)

0.279

 Stage 2A

1 (16.7)

2 (33.3)

3 (50.0)

0 (0.0)

6 (10.0)

 Stage 2B

5 (35.7)

7 (50.0)

2 (14.3)

0 (0.0)

14 (23.3)

 Stage 3A

1 (12.5)

4 (50.0)

3 (37.5)

0 (0.0)

8 (13.3)

 Stage 3B

2 (11.8)

11 (64.7)

2 (11.8)

2 (11.8)

17 (28.3)

 Stage 4A

0 (0.0)

0 (0.0)

2 (66.7)

1 (33.3)

3 (5.0)

 Stage 4B

2 (22.2)

4 (44.4)

3 (33.3)

0 (0.0)

9 (15.0)

Histopathological cancer grades

 Well differentiated SCC

2 (16.7)

5 (41.7)

5 (41.7)

0 (0.0)

12 (20.0)

0.633

 Poorly differentiated SCC

3 (15.0)

10 (50.0)

6 (30.0)

1 (5.0)

20 (33.3)

 Moderately differentiated SCC

4 (30.8)

7 (53.8)

2 (15.4)

0 (0.0)

13 (21.7)

 Endometrium adenocarcinoma

1 (9.1)

6 (54.5)

2 (18.2)

2 (18.2)

11 (18.3)

 Endocervical adenocarcinoma

1 (100)

0 (0.0)

0 (0.0)

0 (0.0)

1 (1.7)

 Metastatic adenocarcinoma

0 (0.0)

1 (50.0)

1 (50.0)

0 (0.0)

2 (3.3)

 Ovarian mucinous cyst adenocarcinoma

0 (0.0)

1 (100)

0 (0.0)

0 (0.0)

1 (1.7)

  1. SCC Squamous Cell Carcinoma